Identification | Back Directory | [Name]
Methyl-5-deoxy-2,3-O-isopropylidene-beta-D-ribofuranoside | [CAS]
23202-81-5 | [Synonyms]
Einecs 245-485-1 B-D-RIBOFURANOSIDE, CapecitabineImpurity34 5-Deoxy-2,3-O-isopropylidene-D-ribofuranoside 1-O-Methyl-2,3-O-isopropylidene-5-Deoxy-β-D-Ribose 1-O-Methyl-2,3-O-isopropylidene-5-Deoxy-beta-D-ribose Methyl-5-desoxy-2,3-O-isopropyliden-β-D-ribofuranosid Methyl-5-deoxy-2,3-O-isopropylidene-β-D-ribofuranoside Methyl 5-deoxy-2,3-O-isopropylidene-b-D-ribofuranoside methyl 5-deoxy-2,3-o-isopropylidene-|A-d-ribofuranoside Methyl 2-O,3-O-isopropylidene-5-deoxy-β-D-ribofuranoside methyl 5-deoxy-2,3-O-isopropylidene-beta-D-ribofuranoside "5-deoxy-2,3-O-isopropylidene-1-O-methyl--D-ribofuranose" β-D-Ribofuranoside,methyl5-deoxy-2,3-O-(1-methylethylidene)- b-D-Ribofuranoside, Methyl5-deoxy-2,3-O-(1-Methylethylidene)- Methyl 2-O,3-O-(1-methylethylidene)-5-deoxy-β-D-ribofuranoside (3aR,6R,6aR)-4-methoxy-2,2,6-trimethyltetrahydrofuro[3,4-d][1,3]dioxole (R)-1-((4R,5S)-5-(methoxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol β-?D-?Ribofuranoside, methyl 5-?deoxy-?2,?3-?O-?(1-?methylethylidene)?- (3aR,4R,6R,6aR)-4-Methoxy-2,2,6-triMethyltetrahydrofuro[3,4-d][1,3]dioxole (3aR,4R,6R,6aR)-4-methoxy-2,2,6-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole | [EINECS(EC#)]
245-485-1 | [Molecular Formula]
C9H16O4 | [MDL Number]
MFCD08703329 | [MOL File]
23202-81-5.mol | [Molecular Weight]
188.22 |
Chemical Properties | Back Directory | [Boiling point ]
225.6±40.0 °C(Predicted) | [density ]
1.11±0.1 g/cm3(Predicted) | [vapor pressure ]
23.49-34.88kPa at 20-25℃ | [storage temp. ]
2-8°C | [solubility ]
Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly) | [form ]
Oil | [color ]
Colourless | [LogP]
1.177-1.259 at 25℃ | [Surface tension]
65.78mN/m at 1g/L and 20℃ |
Hazard Information | Back Directory | [Uses]
Methyl-5-deoxy-2,3-O-isopropylidene-β-D-ribofuranoside is an impurity of Capecitabine(C175650) which is an antineoplastic agent. Capecitabine is a prodrug of Doxifluridine (D556750). |
|
|